drugset / Trial / NCT02119676
Study of Ruxolitinib in Colorectal Cancer Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
Timeline
- Start
- 2014-03
- Primary completion
- 2016-02
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |
| Background | Regorafenib | Small molecule | 160 mg | — |